The North America Motion Sickness Treatment Market would witness market growth of 2.5% CAGR during the forecast period (2023-2029).
The market's growth is anticipated to be propelled by untapped, emerging markets with high potential, owing to the presence of enhanced healthcare infrastructure, rising unmet healthcare demands, and a surge in need for efficient motion sickness medication.
Furthermore, certain demographics may be more susceptible to motion sickness symptoms, such as expectant mothers and individuals between the ages of 2 and 12. The initial indications of motion sickness encompass queasiness, heightened salivation, burping, perspiration, hyperventilation, and a general sense of discomfort. Motion sickness can be prevented or treated through pharmacological therapies such as anticholinergic drugs, antihistaminic drugs, and various other medications.
The North American over-the-counter drugs sector is experiencing growth due to the rising trend of individuals choosing OTC drugs for minor complications instead of seeking intensive treatment from healthcare professionals. This trend is particularly prevalent in countries such as the U.S., Canada, and Mexico. Furthermore, the emergence of numerous mid-size and small players in the region has led to the introduction of innovative medications at reduced prices, thereby enhancing the over-the-counter drugs sector in the region. The wider usage of OTC, like antihistamines, by general consumers for various minor health issues like motion sickness is expected to propel the motion sickness treatment market growth in the region.
The US market dominated the North America Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $131.6 Million by 2029. The Canada market is poised to grow at a CAGR of 4.5% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 4.3% during (2023 - 2029).
Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Motion Sickness Treatment Market is Projected to reach USD 481 Million by 2029, at a CAGR of 3.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).
By Drug Class
By Route of Administration
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
